Figure 2.
CD300a promotes signaling and inhibits platelet aggregations via CD148. (A) s5-CD300a (40 nM) increases global phosphorylated tyrosine (p-Tyr) in unactivated platelets in the presence of secondary mediator inhibitors (n = 3). (B) s5-CD300a (40 nM, 200 nM for monomer) inhibits rhodocytin-induced (50 nM) platelet aggregation in humans and mice, which is abolished by anti-human/mouse CD148 antibody (10 µg/mL) (n ≥ 3). (C) s5-CD300a, not a control protein s5-CD200, inhibits Src and Lat phosphorylation by rhodocytin (n = 3). (D) s5-CD300a (40 nM, 200 nM for monomer) inhibits rhodocytin-induced (50 nM) platelet aggregation in human platelet-rich plasma. (E) s5-CD148 induces CD300a tyrosine phosphorylation in CD300a-transfected HEK293T cells. IP, immunoprecipitation; ′′, minutes.

CD300a promotes signaling and inhibits platelet aggregations via CD148. (A) s5-CD300a (40 nM) increases global phosphorylated tyrosine (p-Tyr) in unactivated platelets in the presence of secondary mediator inhibitors (n = 3). (B) s5-CD300a (40 nM, 200 nM for monomer) inhibits rhodocytin-induced (50 nM) platelet aggregation in humans and mice, which is abolished by anti-human/mouse CD148 antibody (10 µg/mL) (n ≥ 3). (C) s5-CD300a, not a control protein s5-CD200, inhibits Src and Lat phosphorylation by rhodocytin (n = 3). (D) s5-CD300a (40 nM, 200 nM for monomer) inhibits rhodocytin-induced (50 nM) platelet aggregation in human platelet-rich plasma. (E) s5-CD148 induces CD300a tyrosine phosphorylation in CD300a-transfected HEK293T cells. IP, immunoprecipitation; ′′, minutes.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal